Global Lymphoma Therapeutics Market to Exceed $11 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

GIA announces the release of a comprehensive global report on Lymphoma Therapeutics markets. The world market for lymphoma therapeutics is projected to exceed $11 billion by the year 2015. Rising incidence and mortalities associated with the condition is creating considerable demand for drugs used in treating the condition. Market growth is largely being driven by increasing use of currently available immunotherapeutic drugs, and is likely to be further supported by new drug launches in the near future.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Quote startLymphoma Therapeutics: A Global Strategic Business ReportQuote end

San Jose, CA (PRWEB) March 31, 2010

Lymphoma represents a fatal disease with about 1.7 million people suffering from the condition worldwide. In US, lymphomas is the second fastest growing cancer type in terms of incidence and mortality. More than half a million Americans suffer from this condition and the number is expected to rise in the years to follow. Globally, Rituxan, also known as MabThera, continues to be the major choice for treating various forms of lymphomas. However, a huge unmet need persists in lymphoma treatment, which is driving pharmaceutical companies to develop novel drugs. Treatment options such as chemotherapy and monoclonal antibodies have been aggressively used for several years in the treatment of lymphoma.

Europe dominates the world lymphoma therapeutics market as stated by the new market research report on lymphoma therapeutics. In 2009, about 71 thousand new NHL cases were reported in Europe. Growing prevalence and incidence of various types of lymphomas is expected to propel growth of lymphoma therapeutics in Europe. The region represents an estimated 47% of the global market for lymphoma therapeutics in 2009.

Key players profiled in the report include Biogen Idec, Cell Therapeutics Inc., Chugai Pharmaceutical Co. Ltd., Eisai Ltd., F. Hoffmann-la Roche Ltd., Genentech Inc., Genzyme Corp., GlaxoSmithKline Plc., ImmunoGen Inc., and Millennium Pharmaceuticals Inc.

The report titled "Lymphoma Therapeutics: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of lymphoma disease, the treatment, the available drugs, pipeline drugs, major players, drug approvals, and recent industry activity. The study analyzes market data and analytics in terms of value sales for regions including The United States, Europe, and Rest of World.

For more details about this comprehensive market research report, please visit -
http://www.strategyr.com/Lymphoma_Therapeutics_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press(at)StrategyR(dot)com
Web Site http://www.StrategyR.com/
###

Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
PDF Version PDF Printer Friendly VersionPrint

Contact

Attachments

Press Release Attachment

Global Industry Analysts, Inc.



Please visit our website